D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

Several media outlets recently pulled down stories after discovering they were created with AI and falsely attributed to a supposed freelance journalist. According to a report from Press Gazette, six outlets—including Business Insider andWired—deleted articles credited to a writer named "Margaux Blanchard," who now appears to be a fictitious persona. One of the Wired articles taken down was a story about a Chicago-based officiant named Jessica Hu who specialized in digital ceremonies on platforms such as VRChat, Twitch, and Discord. In a note to readers, the outlet stated that after further review, the article did not live up to its publishing standards. Neither The Guardian nor Press Gazette was able to verify that Hu exists. This is not the first time AI-created content has caused trouble in journalism. Earlier this year, the Chicago Sun-Times mistakenly published an AI-generated book list. These revelations of AI-generated content being passed off as work of humans raises concerns about the potential misuse of AI. Companies like D-Wave Quantum Inc. (NYSE: QBTS) that are working to commercialize different quantum computing solutions could have new avenues to explore by providing ways that such fictitious writers can be quickly detected before they provide misleading information that dents the reputation of trusted news outlets. 

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

• Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
• Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
• Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Tuesday's trading session at $15.45, up 2.8628%, on 23,348,112 volume. The average volume for the last 3 months is 40,015,091 and the stock's 52-week low/high is $0.8/$20.56.

Recent News

• D-Wave Quantum Inc. (NYSE: QBTS) - D-Wave Quantum Inc. (NYSE: QBTS) Targets Processor Development Scalability with Advanced Cryogenic Packaging Initiative
• Researchers Use AI to Improve RNA Nanoparticle Design
• Perplexity Wants to Buy Chrome for $34.5 Billion

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

CEO reports confidence about late-stage rare disease pipeline and upcoming key development milestones.

Soligenix's recent accomplishments reflect substantial momentum across its specialized biotherapeutics and public health solutions business segments.

The company's pipeline diversification strategy extends beyond CTCL treatment to encompass multiple therapeutic areas.

With pivotal phase 3 cancer trial results due in 2026 and multiple fast-tracked therapies advancing through late-stage development, Soligenix (NASDAQ: SNGX) stands at the threshold of potentially transforming treatment paradigms for rare diseases affecting millions of underserved patients worldwide. The Soligenix pipeline includes a novel photodynamic drug therapy, along with other innovative drug and vaccine technology, to tackle medical challenges where conventional treatments have failed to deliver meaningful solutions, recently reported on its progress so far this year ( https://ibn.fm/1dhGj ).

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Tuesday's trading session at $3.14, up 0.3194888%, on 361,078 volume. The average volume for the last 3 months is 25,532,263 and the stock's 52-week low/high is $1.09/$6.2299.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - Soligenix Inc. (NASDAQ: SNGX) Reports Major Clinical Trial Milestones, Strategic Progress in Rare Disease Treatment Pipeline
• BioMedNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Awarded FDA Orphan Drug Designation for Dusquetide in Behçet's Disease
• Study Finds That Low BSA Psoriasis Could Have a High Disease Burden

Massimo Group (NASDAQ: MAMO)

The QualityStocks Daily Newsletter would like to spotlight Massimo Group (NASDAQ: MAMO).

Massimo Group (NASDAQ: MAMO) , a manufacturer and distributor of powersports vehicles, announced its successful participation at the Mid-States 2025 Rendezvous, held August 20–21 in Phoenix, Arizona. A partner of Mid-States for more than six years, Massimo used the event to strengthen relationships, align on growth opportunities, and present upcoming product launches, including the HVAC Sentinel Series, enclosed MVR Golf Carts with integrated air conditioning, and the T-Boss 900L Crew UTV. Management said the show reinforced Massimo's commitment to delivering feature-rich, high-performance products while positioning the company for strong Q4 sales and momentum heading into 2026.

To view the full press release, visit https://ibn.fm/6nFtU

Massimo Group (NASDAQ: MAMO) is a prominent manufacturer and distributor specializing in powersports vehicles and recreational watercraft. Established in 2009, the company has built a reputation for delivering value-packed utility terrain vehicles (UTVs), all-terrain vehicles (ATVs), and on-road vehicles to both recreational enthusiasts and professionals in the agricultural sector. In 2020, Massimo expanded its offerings by launching Massimo Marine, dedicated to crafting high-quality watercraft with advanced designs and exceptional customer service.

Massimo Group is focused on sustainability. Its recent initiatives, including the introduction of the MVR Series of electric carts, highlight the company’s commitment to eco-friendly solutions that address growing consumer demand for sustainability in the powersports and marine industries.

The company’s manufacturing capabilities have also evolved significantly. Its expanded 376,000-square-foot facility in Garland, Texas, now features advanced automation, including a vehicle assembly robot line. This addition is expected to significantly enhanced production capacity and efficiency, enabling Massimo to scale its operations and better meet market demand.

Product Portfolio

Massimo Group’s product portfolio showcases its dedication to innovation and versatility. Its diverse lineup combines advanced features, sustainability, and value to meet the needs of a dynamic market.

• Massimo Motor: This category includes a wide range of UTVs, ATVs, go-karts, and mini-bikes designed for both recreational and practical applications. Notable recent additions include the T-Boss 1000 UTV, which combines rugged performance with advanced features, and the GKD 350 All-Terrain Go-Kart, a versatile two-seater ideal for various terrains. The Buck 550-6 Crew, a six-seater UTV, further expands this lineup, providing comfort and utility for families and light-duty users at an accessible price point.
• Massimo Marine: Specializing in pontoon and tritoon boats, this division emphasizes luxury and performance. A recent collaboration between Massimo and Vision Marine Technologies has introduced electric pontoon platforms, catering to consumers seeking eco-friendly watercraft for both commercial and recreational use.
• Massimo Electric: Reflecting the company’s commitment to sustainability, Massimo Electric focuses on low-speed electric vehicles (LSVs) tailored for diverse applications. Recent launches include the MVR 2X Golf Cart and MVR Cargo Max Utility Cart, which deliver advanced features and versatility for recreational users and professionals in industries like farming and groundskeeping.

By combining practicality with cutting-edge design, Massimo Group seeks to set the standard in the powersports and marine industries.

Market Opportunity

The global ATV and UTV market is experiencing robust growth, with North America projected to reach approximately $9.18 billion in 2024 and expand at a compound annual growth rate (CAGR) of 7.8% to $13.37 billion by 2029, according to Mordor Intelligence. Likewise, the U.S. electric UTV and ATV powertrain market is rapidly expanding. It was valued at $2.46 billion in 2022 and is expected to grow at a CAGR of 10.2%, reaching $5.18 billion by 2030, as reported by Grand View Research.

The pontoon boat market complements this growth, driven by increased interest in leisure and marine tourism. The market size exceeded $7.9 billion in 2022 and is projected to grow at a CAGR of 8.3% through 2032, according to Global Market Insights. Massimo Marine’s introduction of electric pontoon platforms through its Vision Marine partnership is expected to position the company to effectively address this growing market segment.

With strategic partnerships and an expanding dealer network, Massimo believes it is poised to penetrate deeper into domestic and international markets. The company’s service coverage currently includes over 2,800 retail locations, 600 motor service centers, and 5,500 marine service centers, ensuring robust support and accessibility for customers. This extensive distribution network underpins Massimo’s ability to capture market share and drive sustained growth.

Leadership Team

David Shan, Founder, Chairman, and CEO, established Massimo Motor in 2009 and Massimo Marine in 2020. He has led the company through significant growth phases, including the development of diverse product lines and its public listing. Shan holds a bachelor’s degree in international trade from Qingdao Ocean University of China.

Dr. Yunhao Chen, CPA, serves as the company’s Chief Financial Officer, bringing extensive experience in capital markets, financial reporting, and corporate governance since her appointment in May 2023. She holds a Ph.D. in Accounting and an MBA in Finance from the University of Minnesota.

Michael Smith, Vice President, joined Massimo in 2019 and played a pivotal role in launching Massimo Marine. With a strong background in powersports retail and product innovation, he is dedicated to driving new product development. Smith studied International Business and Marketing at the University of California, San Diego.

Massimo Group (NASDAQ: MAMO), closed Tuesday's trading session at $2.99, up 0.6734007%, on 3,328 volume. The average volume for the last 3 months is 25,011 and the stock's 52-week low/high is $1.839/$4.6599.

Recent News

• Massimo Group (NASDAQ: MAMO) - InvestorNewsBreaks - Massimo Group (NASDAQ: MAMO) Showcases New Products and Growth Strategy at Mid-States 2025 Rendezvous
• Massimo Group (NASDAQ: MAMO) Accelerates Golf Cart Market Reach with Vietnam Partnership
• Why Ford May Be Ramping Up Its EV Investments

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

The U.S. remains heavily dependent on China for rare earth processing and refined components critical to defense, electronics and clean-energy applications.

An independent evaluation confirmed that RapidSX can separate both light and heavy REEs using proven conventional chemistry but dramatically faster kinetics.

Ucore's broader vision includes disrupting China's control over the REE industry by introducing scalable, high-efficiency separation technology.

The race to secure rare earth elements has become a matter of both economic survival and national security for the United States, as China continues to dominate the global supply chain for these critical resources. At the center of America's push to break free from this dependence is Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) , whose RapidSX(TM) technology offers a faster, more efficient way to separate rare earths and build a resilient domestic supply chain.

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) s a critical metals technology company developing scalable rare earth element (“REE”) refining infrastructure in North America. Originally founded in 2006 as a mineral exploration company, Ucore has since evolved into a processing technology innovator focused on commercializing its proprietary RapidSX™ platform under a $18.4 million contract from the U.S. Department of Defense, with additional support from Natural Resources Canada. The company’s flagship deployment is the Louisiana Strategic Metals Complex (“SMC”), with additional SMCs planned to follow.

Ucore’s mission is to help reestablish a domestic REE supply chain by offering competitive, modular processing solutions that reduce dependence on China. Supported by government funding, private capital, and engineering partnerships, Ucore aims to meet growing demand for rare earth oxides in electric vehicles, defense systems, and advanced energy technologies.

The company is headquartered in Halifax, Nova Scotia.

Projects & Technology

RapidSX™ Separation Technology

RapidSX™ is Ucore’s proprietary rare earth separation platform, delivering three times faster processing than traditional solvent extraction (SX) methods. Its current demonstration program in Kingston, Ontario, is being conducted under contract with the U.S. Department of Defense to prove commercial readiness for processing both heavy and light REEs. The project is also supported by Natural Resources Canada.

RapidSX™ employs a column-based design that eliminates the need for powered mixer-settlers, enabling a smaller facility footprint, quicker commissioning, and lower CAPEX and OPEX. The platform is adaptable to light and heavy REE feedstocks and is structured for modular scale-up.

The 52-stage RapidSX™ Commercial Demonstration Plant in Kingston, Ontario—operated in partnership with Kingston Process Metallurgy—has logged thousands of runtime hours and is currently processing rare earth feedstock further to the company’s U.S. Department of Defense contract. In January 2025, Ucore secured a $500,000 non-dilutive grant from Ontario’s Critical Minerals Innovation Fund to support the advancement of the Kingston facility and, in the words of Ontario Mines Minister George Pirie, “build a secure supply chain ready to fuel the technologies of tomorrow.”

Strategic Metals Complex – Louisiana

Ucore has selected an 80,800-square-foot brownfield site within the England Airpark in Alexandria, Louisiana, as the location for its first commercial rare earth refining facility. The Louisiana SMC is expected to scale from 2,000 tonnes per annum (TPA) of total rare earth oxides initially to 5,000 TPA, with potential to ultimately reach 7,500 TPA.

The facility benefits from Foreign Trade Zone (FTZ) status, reducing tariff burdens on imported inputs and enhancing logistics efficiency. In addition to these structural advantages, the state of Louisiana has outlined an incentive package valued at $15 million, including a $900,000 infrastructure grant and $360,000 in additional local support. The project is expected to create 100 family-wage jobs and has received strong support from federal and state officials.

To date, Ucore has secured $2.3 million in milestone payments under its $18.4 million OTA award from the U.S. Department of Defense. In early 2024, the company also secured C$2.16 million in private investment from Hondo Private Equity to support its commercialization efforts.

Bokan-Dotson Ridge REE Project – Alaska

Ucore maintains 100% ownership of the Bokan-Dotson Ridge heavy REE project in Southeast Alaska. A Preliminary Economic Assessment was completed in January 2013. The Alaska Industrial Development and Export Authority (AIDEA) has authorized $145 million in bond financing under SB99 (2014) to support future development.

While Bokan remains a long-term asset, Ucore continues to advance it at a measured pace, complementing its near-term focus on commercial rare earth refining and oxide production at the Louisiana SMC.

Market Opportunity

According to Grand View Research, the global rare earth elements market was estimated at $3.95 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030. The market outlook remains strong, fueled by the growing demand for permanent magnets and catalysts in the automotive sector.

In March 2025, President Trump invoked the Defense Production Act to prioritize domestic critical mineral production, signaling a national mandate to reduce reliance on “hostile foreign powers’ mineral production.” One month later, the Chinese government enacted immediate export restrictions on seven key rare earth elements, including dysprosium and terbium, further intensifying pressure on Western nations to develop secure and independent supply chains. This underscores the strategic value of Ucore’s domestic separation infrastructure.

Leadership Team

Pat Ryan, P.Eng., Chairman and CEO, is the founder of Neocon International, a leading automotive OEM supplier. He brings over 25 years of experience in global supply chain innovation and has led Ucore since 2014 in its strategic pivot toward rare earth processing.

Peter Manuel, Vice President, CFO & Corporate Secretary, has served as Ucore’s financial lead for 14 years. Trained as a Chartered Accountant, with extensive experience across Canada, England, and Ireland, Mr. Manuel has advised public and private entities on strategic planning, treasury, and assurance.

Michael Schrider, MEng, P.E., Vice President & COO, is a multidisciplinary engineer with over 30 years of experience. He founded and operated engineering firms SAi and ABD and has overseen all phases of Ucore’s technical development since 2016.

Geoff Atkins, Vice President of Business Development, has 30 years of mining experience and was instrumental in advancing both Lynas’ Mt. Weld and Vital Metals’ Nechalacho REE operations. He brings deep operational knowledge and leads feedstock strategy at Ucore.

Ucore Rare Metals Inc. (OTCQX: UURAF), closed Tuesday's trading session at $2.7415, up 16.1653%, on 1,899,560 volume. The average volume for the last 3 months is 912,490 and the stock's 52-week low/high is $0.33/$2.88.

Recent News

• Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) - Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Leads U.S. Effort to Reduce REE Dependence with Transformative Technology
• RockBreaks - RapidSX(TM) Powers Ucore Rare Metals Inc.'s (TSX.V: UCU) (OTCQX: UURAF) Role in Rebuilding Mineral Independence
• MiningNewsBreaks - Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Rises as Key Player in Critical Materials with RapidSX(TM)

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT).

HeartBeam (NASDAQ: BEAT) has secured foundational clearance from the U.S. Food and Drug Administration ("FDA") for its patented HeartBeam system. "The first cable-free, high-fidelity ECG device that captures the heart's electrical activity from three distinct directions, the HeartBeam system enables patients and physicians to access critical arrhythmia data outside traditional clinical settings," reads a recent article. "With the clearance secured, HeartBeam plans to expand access through early access programs, deploy field-testing among medical practices and ultimately commercialize the system. The anticipated sequence of steps includes physician training, system support and data collection to streamline regulatory and commercial readiness. With a transformative roadmap in place, HeartBeam is positioned to redefine the future of cardiac care, taking it outside the hospital and putting it into the hands of patients and clinicians alike."

To view the full article, visit https://ibn.fm/CpHP8

HeartBeam Inc. (NASDAQ: BEAT) is a medical technology company developing a groundbreaking solution for at-home detection and monitoring of cardiac conditions. The company is creating the first ever cable-free synthesized 12-lead ECG platform designed to give patients the ability to record their symptoms the moment they occur, wherever they are. By providing synthesized, 12-lead ECG data, physicians can quickly assess the symptoms and ensure patients get the care they need in a timely manner. It also eliminates the need for wires, complex setup, or clinical staff, thus allowing synthesized 12-lead ECG signals to be accessible outside of a medical setting.

HeartBeam’s vision is to redefine cardiac care by enabling early detection, proactive monitoring, and informed clinical decisions outside the confines of a traditional medical setting. Its patented approach not only delivers similar, but not identical, accuracy of conventional 12-lead ECGs for arrhythmia detection but also unlocks future capabilities in ischemia detection, AI-assisted analysis, and longitudinal cardiac trend tracking.

The HeartBeam System is now FDA cleared for arrhythmia assessment, following foundational 510(k) clearance granted in December 2024. The company submitted a 510(k) application for its 12-lead ECG synthesis software in January 2025 for arrhythmia assessment. As it approaches commercialization, HeartBeam is executing a multi-phase go-to-market strategy with initial U.S. rollout plans and a focus on high-margin, recurring revenue.

The company is headquartered in Santa Clara, California.

Products

HeartBeam’s flagship product is a credit card-sized, cable-free device designed to capture ECG signals in three non-coplanar directions and transform them into synthesized 12-lead ECGs. This novel form factor integrates a smartphone app, cloud connectivity, and a physician portal, enabling patients to record cardiac events at the moment symptoms occur and physicians to assess and triage in near real time.

The device is supported by an expanding software ecosystem. A key component of this is HeartBeam’s proprietary 12-lead ECG synthesis software, which met its clinical endpoint in the VALID-ECG pivotal study with 93.4% manual diagnostic agreement for arrhythmia assessment. This software is currently under FDA review and is designed to deliver clinical-grade arrhythmia diagnostic capabilities outside of traditional healthcare environments.

In April 2025, HeartBeam announced a strategic partnership with AccurKardia to incorporate its FDA-cleared ECG analysis software, AccurECG™, into HeartBeam’s offering. This integration is expected to enhance automated rhythm interpretation, streamline physician workflows, and improve diagnostic speed and accuracy.

Additional form factors are under development, including an on-demand synthesized 12-lead patch with issued patents, intended to serve the extended-wear market segment. These complementary offerings are intended to support chronic disease management and continuous monitoring applications, broadening HeartBeam’s total product ecosystem in the future.

Market Opportunity

HeartBeam is targeting large and growing segments within the $20 billion+ global cardiac monitoring and diagnostics market. According to the company’s own materials, the U.S. concierge care segment alone represents a $500 million serviceable addressable market (SAM), comprising approximately 1.5 million patients—500,000 of whom are at elevated cardiac risk. This initial focus provides a strategic entry point for cash-pay and early adoption.

Expanding beyond this niche, HeartBeam identifies a $1.3 billion to $2.6 billion annual opportunity in the broader U.S. direct patient pay market, driven by more than 2.6 million high-income individuals aged 35–74 with elevated cardiac risk. For comparison, more than 2.5 million Oura rings and over 3 million AliveCor Kardia devices have been sold, demonstrating strong consumer willingness to adopt personal cardiac technologies.

HeartBeam’s long-term opportunity is significantly larger. The company estimates that over 20 million people in the U.S. are at high risk for myocardial infarction (MI), representing a total addressable market nearly 40 times greater than the concierge segment. Additionally, the company’s on-demand 12-lead patch aims to capture market share in the extended wear and mobile cardiac telemetry (MCOT) space, competing with incumbents like iRhythm, Boston Scientific, Philips, and Baxter.

Leadership Team

Robert P. Eno, Chief Executive Officer and Director, brings over 30 years of experience launching disruptive medical technologies and leading commercialization efforts. He has held executive roles at HeartFlow, OptiMedica, NeoGuide Systems, and Avantec Vascular, and holds an MBA and BA from Stanford University.

Branislav Vajdic, PhD, President and Founder, is a seasoned innovator with over three decades of experience in technology and device development. He co-invented flash memory at Intel and led engineering teams responsible for the Pentium processor series. He previously served as CEO of NewCardio and holds a PhD in Electrical Engineering from the University of Minnesota.

Timothy Cruickshank, Chief Financial Officer, has over 15 years of experience in financial and strategic leadership roles. Formerly CFO at ImpediMed, he transformed the company into a SaaS-driven model. He holds an MBA from Keller Graduate School and a BS in Accounting from Syracuse University.

Peter J. Fitzgerald, MD, PhD, Chief Medical Officer, is a Stanford professor emeritus and interventional cardiologist with leadership in over 175 clinical trials and 24 medical startups. He co-founded TriVentures and has advised the FDA for over 20 years.

Ken Persen, Chief Technology Officer, has more than 25 years of experience in cardiac and digital health technology, including founding LIVMOR and leadership roles at Guidant and Cameron Health. He specializes in system design and product engineering for connected cardiac solutions.

HeartBeam Inc. (NASDAQ: BEAT), closed Tuesday's trading session at $1.15, up 4.5455%, on 37,445 volume. The average volume for the last 3 months is 109,102 and the stock's 52-week low/high is $0.9101/$3.48.

Recent News

• HeartBeam Inc. (NASDAQ: BEAT) - InvestorNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Paves Way to Redefine Cardiac Care
• BioMedNewsBreaks - HeartBeam Inc.'s (NASDAQ: BEAT) IP Momentum Continues with New Patents Advancing 3D ECG Technology
• BioMedNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Reports Q2 2025 Results, Advances Toward FDA Clearance and Commercial Launch

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF)

The QualityStocks Daily Newsletter would like to spotlight Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF).

Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) announced that the Federal Bureau of Land Management has deemed the Company's Exploration Plan of Operations complete, allowing the Santa Fe Mine Project in Nevada to advance into full environmental assessment under the National Environmental Protection Act. The determination confirms completion of all baseline biological, cultural and historical studies, which can also support future mine planning. The plan provides for exploration across 12 square kilometers with more than 700 drill sites. Lahontan anticipates completing the NEPA process and receiving final approval of the plan in Q4 2025, enabling a robust drilling campaign in 2026.

To view the full press release, visit https://ibn.fm/CR2Bb

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) is a Canadian mine development and exploration company advancing a portfolio of gold and silver assets in Nevada’s Walker Lane, one of the world’s most productive and mining-friendly regions. Through its U.S. subsidiaries, the company controls four gold and silver properties in Nevada, three of which are 100%-owned and one controlled via a low-cost option to acquire full ownership. With a clear near-term path to production, Lahontan is focused on unlocking oxide gold and silver value from past-producing, infrastructure-rich projects.

The company’s mission is to responsibly develop and expand its oxide resources while minimizing capital intensity and maximizing economic returns. Leveraging a strong technical team with a track record of advancing projects and building mines, Lahontan is focused on growing gold and silver resources and hitting permitting milestones across multiple sites. Its strategy prioritizes scalability, efficiency, and timely value realization for shareholders.

By maintaining full project ownership and a capital-light development model, Lahontan Gold is positioned to rapidly transition from development to production.

The company is headquartered in Toronto, Ontario.

Projects

Santa Fe Mine

The 26.4 km² Santa Fe Mine is Lahontan’s flagship asset and core development priority. A past-producing open-pit, heap-leach gold and silver operation, Santa Fe historically yielded more than 359,000 ounces of gold and 702,000 ounces of silver between 1988 and 1995. The site benefits from established infrastructure—including power, water, and road access—and more than 79% of its known resources are unencumbered by royalties.

A 2024 NI 43-101 resource estimate outlines 1.54 million ounces of gold equivalent (AuEq) in the Indicated category and 0.41 million ounces Inferred, all pit-constrained. Oxide resources average among the highest grades in the state and are distributed across five known deposits. A 2025 Preliminary Economic Assessment (PEA) projects strong economic returns, including an after-tax NPV5% of $200 million, a 34.2% internal rate of return (IRR), and average annual production of approximately 50,000 ounces AuEq over an eight-year mine life.

Permitting is well underway for both the Exploration and Mine Plans of Operation, covering over 12 km² and more than 700 drill holes. The company is targeting construction permits in late 2026 and continues to pursue oxide resource expansion and metallurgical optimization, particularly within the Slab-Calvada corridor.

West Santa Fe

West Santa Fe lies just 13 kilometers from the flagship and is being explored as a potential satellite operation. The project is defined by a shallow, oxide-dominant gold-silver system with a conceptual target of 0.5 to 1.0 million ounces AuEq based on historic drilling and recent surface sampling, which returned up to 2.61 g/t Au and 899 g/t Ag (14.6 g/t AuEq). A 6,300-meter Phase One reverse circulation drill program is scheduled for 2025 to validate historical data and support a maiden resource estimate. Development is streamlined under a low-cost option agreement and a rapid permitting path via Notice of Intent.

Moho and Redlich

The Moho and Redlich projects provide additional longer-term upside within Lahontan’s portfolio. Moho features high-grade, oxidized epithermal veins with historic production at grades of 20–25 g/t Au and 300 g/t Ag. A 2019 core drill program confirmed the presence of high-grade mineralization at depth. Redlich, located along trend from the historic Candelaria silver mine, hosts disseminated Ag mineralization in epithermal veins and hydrothermal breccias but remains untested by drilling. While no near-term programs are currently disclosed, both assets represent future exploration optionality.

Market Opportunity

Lahontan Gold operates in Nevada, consistently ranked the top global mining jurisdiction by the Fraser Institute due to its transparent permitting process, legal stability, and established infrastructure. Nevada produces over 4.5 million ounces of gold annually, generating approximately $9 billion in value, and ranks fifth globally in total gold production.

According to the World Gold Council, total gold demand in Q1 2025 reached 1,206 tonnes, up 1% year-over-year, marking the strongest first quarter since 2016. Central banks added 244 tonnes to reserves, a slight slowdown from the prior quarter but well within the strong buying range observed over the past three years. Meanwhile, silver demand is supported by strong industrial usage in solar panels, electric vehicles, and semiconductors, with long-term deficits forecast in the physical silver market.

With macro-driven demand for gold, technology-driven silver consumption, and strong institutional buying across both metals, Lahontan is uniquely positioned to capitalize through its portfolio of oxide-focused projects in a top-tier jurisdiction—offering near-term production potential and longer-term resource expansion.

Leadership Team

Kimberly Ann, Founder, CEO, President & Executive Chair, is a veteran mining executive with a track record of founding and scaling junior resource companies. She has raised over $210M in financing and led the $340M buyout of Prodigy Gold. Her prior roles include CFO of PPX Mining and founder of Latin America Resource Group, which merged with Carube Copper to form C3 Metals.

Brian Maher, Founder and VP of Exploration, is an economic geologist with more than 45 years of experience. He previously led Prodigy Gold as CEO, where he helped develop the Magino gold project before its $341M acquisition. His career includes senior roles at ASARCO, Hochschild Mining, and PPX Mining, where he oversaw exploration and production in the Americas.

John McNeice, Chief Financial Officer, is a Chartered Professional Accountant with three decades of experience in public company reporting. He has served as CFO for seven public resource companies and played a key role in Ur-Energy Inc.’s TSX IPO and $150M in financings. He also serves as CFO for Gold79 Mines, C3 Metals, and Northern Graphite Corp.

Lahontan Gold Corp. (OTCQB: LGCXF), closed Tuesday's trading session at $0.0912, up 6.0465%, on 1,811,270 volume. The average volume for the last 3 months is 712,690 and the stock's 52-week low/high is $0.0143/$0.097.

Recent News

• Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) - MiningNewsBreaks - Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Santa Fe Mine Project Advances to Full Environmental Assessment Under NEPA
• MiningNewsBreaks - Proven Past, Strategic Future: Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Advances Santa Fe Toward Restart
• InvestorNewsBreaks - Lahontan Gold Corp. (TSXV: LG) (OTCQB: LGCXF) Signs Binding Term Sheet to Acquire York Claims Adjoining Santa Fe Mine Project

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

According to new research conducted by a team at University College London, blocking the brain damage caused by glioblastoma could keep the patient's brain working better for a much longer time and also slow the pace at which the tumor grows. The study used a mouse model and found that when glioblastoma tumors are in their early stage, they damage axons (parts of the nerves in the brain). When this damage occurs, according to the findings of the researchers, the brain responds to this injury to its nerve cells by first breaking down and then removing those damaged axons from the brain. Unfortunately, these two natural responses only serve to accelerate the rate at which the tumor grows due to the increased inflammation in the brain. With this new link discovered between glioblastoma and neurodegeneration, the methods being studied to treat neurodegenerative diseases could have a role in the treatment of early-stage GBM. Different approaches are being explored by many companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to develop treatments that will be effective against glioblastoma. Hopefully, a breakthrough treatment may be commercialized over the coming years to improve the treatment outcomes of the people diagnosed with this aggressive form of brain cancer. 

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (https://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $6.12, off by 6.422%, on 23,447 volume. The average volume for the last 3 months is 76,052 and the stock's 52-week low/high is $4.93/$221.94.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - Blocking Glioblastoma-Triggered Brain Damage Could Slow the Aggressive Tumor's Growth
• TinyGemsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial
• What Women Need to Know About Benign Brain Tumors

PowerBank Corporation (Cboe CA: SUNN) (FSE: GY2) (NASDAQ: SUUN)

The QualityStocks Daily Newsletter would like to spotlight PowerBank Corporation (Cboe CA: SUNN) (FSE: GY2) (NASDAQ: SUUN).

The three projects, Sydney, Brooklyn, and Petpeswick, will generate a combined 12.4 MW DC of clean energy.

Funding is provided by Nova Scotia's Department of Energy and managed by Net Zero Atlantic.

PowerBank is the lead developer for the owner, working alongside local partner Trimac Engineering.

The projects are part of Canada's first Community Solar Program, targeting 80% renewable energy by 2030.

PowerBank has completed over 100 MW of projects and holds a pipeline exceeding 1 GW across North America.

PowerBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) , a North American energy infrastructure developer and asset owner, announced that its 5.7 MW North Main St ground-mount solar project in upstate New York has completed its Coordinated Electric System Interconnection Review and will now advance to site permitting. The project is expected to qualify for New York's Value of Distributed Energy Resources compensation mechanism with an estimated first-year average rate of US$0.0971/kWh. Once permitted and financed, construction will begin on the community solar initiative, which will deliver clean energy to the local grid while enabling renters, businesses and homeowners to subscribe for bill credits and savings. PowerBank, with over 100 MW of completed projects and a development pipeline exceeding 1 GW, said the project supports New York's Climate Leadership and Community Protection Act goal of 6 GW of solar by 2025.

To view the full press release, visit https://ibn.fm/nrWvh

The U.S. Internal Revenue Service (IRS) has published new tax credit guidance on renewable energy just weeks after the Trump administration accelerated the expiration of numerous green energy-related tax credits via a massive spending and tax bill, plunging the domestic green energy space into crisis. Dubbed the Big Beautiful Bill, the spending legislation set the expiration date for most green energy subsidies and tax credits to August, effectively bringing America's renewable energy tax credit program to a sudden close. The IRS is now releasing new tax credit guidance to help the green energy sector navigate the new, post-Big Beautiful Bill landscape. While industry leaders appreciate that the IRS avoided even more restrictive interpretations, the reality remains stark: this may be the final opportunity to secure federal renewable energy incentives for the foreseeable future. With the expedited expiry of renewable energy incentives in the U.S., companies like PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) now have to use their innovativeness to deliver cutting-edge products that are competitively priced to lure consumers.

PowerBank Corporation (NASDAQ: SUUN) (CSE: SUNN) is a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the United States. The company is committed to advancing the transition to sustainable energy by offering end-to-end services that include project origination, financing structuring, engineering, procurement, construction, and long-term operations and maintenance. PowerBank focuses on delivering innovative energy solutions through solar photovoltaic systems, battery energy storage systems (BESS), and electric vehicle (EV) charging infrastructure.

With a vision to provide scalable and reliable clean energy solutions, PowerBank has established itself as a leader in the renewable energy market by cultivating partnerships with utilities, commercial and industrial entities, municipalities, and residential customers. Its vertically integrated business model allows for optimized efficiency, cost management, and returns across diverse markets in North America. This end-to-end approach ensures greater control over project quality, costs, and operational outcomes, strengthening its competitive position.

Driven by a mission to create a greener future, PowerBank manages a robust portfolio of projects, including more than 100 megawatts (MW) of developed capacity and a pipeline exceeding one gigawatt (GW). The company’s commitment to sustainability and innovation makes it a recognized player in the renewable energy sector.

PowerBank has offices in Toronto, Ontario and New York.

Projects

PowerBank boasts an impressive and diverse portfolio of renewable energy initiatives that underline its leadership in the clean energy space. In the U.S., the company has over 250 MW of solar projects under development, principally in New York, focusing on community solar farms and commercial and industrial installations. Notably, PowerBank is developing several community solar projects in upstate New York, which will deliver clean energy to local residents and small businesses. Community solar projects, which are a cornerstone of PowerBank’s portfolio, provide scalable solutions for renters, homeowners, and small businesses to access affordable renewable energy, driving localized energy independence and economic savings.

In Canada, PowerBank has been a significant participant in Ontario’s Feed-in-Tariff program, where it has secured contracts for close to 200 MW of capacity. Its current management includes 70 solar power projects, totaling 28.8 MW of operational solar assets. The company’s expertise extends to the development and ownership of battery energy storage systems and EV charging stations, further diversifying its portfolio.

The company’s vertically integrated approach spans the entire project lifecycle, from initial site acquisition and grid interconnection to long-term operation and maintenance services. This ensures seamless execution and high-quality outcomes, providing value to stakeholders and supporting the transition to a clean energy future.

Market Opportunity

PowerBank operates within a growing renewable energy market driven by global demand for sustainable power solutions. In North America, favorable policies such as the Inflation Reduction Act in the United States and Canada’s investments in green technologies provide a robust foundation for renewable energy adoption. Solar PV installations and battery energy storage systems are at the forefront of this expansion, addressing energy reliability and grid stability while reducing carbon emissions.

The North American solar PV market was valued at $25.02 billion in 2019 and is projected to reach $120.74 billion by 2027, growing at a compound annual growth rate (CAGR) of 21.7% from 2020 to 2027. Likewise, the global BESS market is expected to expand from $7.8 billion in 2024 to $25.6 billion by 2029, at a CAGR of 26.9%, as reported by MarketsandMarkets. These trends are driven by the increasing integration of renewable energy sources, the need for grid resilience, and declining technology costs.

PowerBank’s operations have it well-positioned to capitalize on these opportunities. With a development pipeline exceeding one gigawatt (GW), the company is focused on meeting growing demand in community and commercial solar sectors. Decentralized energy solutions, such as virtual net metering and behind-the-meter systems, further enhance PowerBank’s market potential by addressing the critical need for flexible, cost-effective, and sustainable energy infrastructure. By leveraging its vertically integrated model and diversified portfolio, PowerBank stands as a key player in driving the renewable energy transition.

Leadership Team

Dr. Richard Lu, MD, MSc., MHSc., MBA, serves as President and CEO of PowerBank, bringing over 25 years of global energy experience. His leadership has been instrumental in advancing the company’s strategic initiatives across North America, Europe, and Asia, with a focus on renewable energy development and operational excellence.

Sam Sun, MBA, is the Chief Financial Officer of PowerBank. A Chartered Professional Accountant with more than 15 years of expertise in corporate finance, Mr. Sun has overseen financial strategies and internal controls across the cleantech, manufacturing, and mining sectors in Canada, the U.S., and China.

Andrew van Doorn, PE, serves as Chief Operating Officer, with nearly three decades of experience in engineering and construction. Mr. van Doorn has successfully led projects totaling over 200 MW of solar capacity and is a former Chairman of the Canadian Solar Industries Association.

Tracy Zheng, MBA, Chief Development Officer, has over 25 years of experience in brand marketing, business development, and solar project operations. She has spearheaded sales initiatives, conducted feasibility studies, and negotiated key partnerships that drive PowerBank’s growth.

Matt Wayrynen, Executive Chairman and Director, has a background in resource company management, venture capital, and mergers and acquisitions. Under his leadership, Solar Flow-Through Funds, where Mr. Wayrynen acted as CEO, was acquired by PowerBank, enhancing its asset portfolio and growth prospects.

---

Forward Looking Statements

This report contains forward-looking statements and forward-looking information ‎within the meaning of Canadian securities legislation (collectively, “forward-looking ‎statements”) that relate to the Company’s current expectations and views of future events. ‎Any statements that express, or involve discussions as to, expectations, beliefs, plans, ‎objectives, assumptions or future events or performance (often, but not always, through the ‎use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will ‎continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, ‎‎”projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be ‎forward-looking statements and may involve estimates, assumptions and uncertainties ‎which could cause actual results or outcomes to differ materially from those expressed in ‎such forward-looking statements. In particular and without limitation, this report ‎contains forward-looking statements pertaining to the Company’s expectations regarding its industry trends and overall market growth of the data center market; the Company’s expansion into the data center market, including its pursuit of opportunities as a developer, owner, and strategic partner in data center infrastructure; supporting the demand for high-performance, sustainable energy solutions within the sector; details of the company’s business plan including development of solar power projects, battery storage projects and EV charging projects; the completion of any contracts for, or construction of, any data center, solar power, battery storage or EV projects; the receipt of interconnection approval, permits and financing to be able to construct projects; the receipt of incentives for projects; and the size of the Company’s development pipeline. No assurance ‎can be given that these expectations will prove to be correct and such forward-looking ‎statements included in this report should not be unduly relied upon. These ‎statements speak only as of the date of this report.‎

Forward-looking statements are based on certain assumptions and analyses made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate, and are subject to risks and uncertainties. In making the forward looking statements included in this report, the Company has made various material assumptions, including but not limited to: obtaining the necessary regulatory approvals; that regulatory requirements will be maintained; general business and economic conditions; the Company’s ability to successfully execute its plans and intentions; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and services offered by the Company’s competitors; that the Company’s current good relationships with its service providers and other third parties will be maintained; and government subsidies and funding for renewable energy will continue as currently contemplated. Although the Company believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and the Company cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements.

Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Forward-‎Looking Statements” and “Risk ‎Factors” in the Company’s most recently completed Annual Information Form, and other public filings of the Company, which include: the Company may be adversely affected by volatile solar power market and industry conditions; the execution of the Company’s growth strategy depends upon the continued availability of third-party financing arrangements; the Company’s future success depends partly on its ability to expand the pipeline of its energy business in several key markets; governments may revise, reduce or eliminate incentives and policy support schemes for solar and battery storage power; general global economic conditions may have an adverse impact on our operating performance and results of operations; the Company’s project development and construction activities may not be successful; developing and operating solar projects exposes the Company to various risks; the Company faces a number of risks involving Power Purchase Agreements (“PPAs”) and project-level financing arrangements; any changes to the laws, regulations and policies that the Company is subject to may present technical, regulatory and economic barriers to the purchase and use of solar power; the markets in which the Company competes are highly competitive and evolving quickly; an anti-circumvention investigation could adversely affect the Company by potentially raising the prices of key supplies for the construction of solar power projects; foreign exchange rate fluctuations; a change in the Company’s effective tax rate can have a significant adverse impact on its business; seasonal variations in demand linked to construction cycles and weather conditions may influence the Company’s results of operations; the Company may be unable to generate sufficient cash flows or have access to external financing; the Company may incur substantial additional indebtedness in the future; the Company is subject to risks from supply chain issues; risks related to inflation; unexpected warranty expenses that may not be adequately covered by the Company’s insurance policies; if the Company is unable to attract and retain key personnel, it may not be able to compete effectively in the renewable energy market; there are a limited number of purchasers of utility-scale quantities of electricity; compliance with environmental laws and regulations can be expensive; corporate responsibility may adversely impose additional costs; the future impact of any resurgence of COVID-19 on the Company is unknown at this time; the Company has limited insurance coverage; the Company will be reliant on information technology systems and may be subject to damaging cyberattacks; the Company may become subject to litigation; there is no guarantee on how the Company will use its available funds; the Company will continue to sell securities for cash to fund operations, capital expansion, mergers and acquisitions that will dilute the current shareholders; and future dilution as a result of financings.

The Company undertakes no obligation to update or revise any ‎forward-looking statements, whether as a result of new information, future events or ‎otherwise, except as may be required by law. New factors emerge from time to time, and it ‎is not possible for the Company to predict all of them, or assess the impact of each such ‎factor or the extent to which any factor, or combination of factors, may cause results to ‎differ materially from those contained in any forward-looking statement. Any forward-‎looking statements contained in this report are expressly qualified in their entirety by ‎this cautionary statement.‎

PowerBank Corporation (NASDAQ: SUUN), closed Tuesday's trading session at $2.23, off by 10.0806%, on 1,068,291 volume. The average volume for the last 3 months is 420,918 and the stock's 52-week low/high is $1.23/$6.43.

Recent News

• PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) - US IRS Publishes New Tax Credit Guidance on Renewable Energy
• PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), Announces $1.74 Million Grant to Advance Nova Scotia Community Solar Projects, for Which PowerBank is Lead Developer
• RockBreaks - PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Advances 5.7 MW North Main St Solar Project in New York Following CESIR Completion

Newton Golf Company Inc. (NASDAQ: NWTG)

The QualityStocks Daily Newsletter would like to spotlight Newton Golf Company Inc. (NASDAQ: NWTG).

Newton Golf Company (NASDAQ: NWTG) was featured in a recent article that discussed its positioning as a premier force in the golf-equipment industry. The article reads: "Newton Golf Company has hit a major milestone in its mission to redefine golf shaft performance — more than 50 professionals across the PGA TOUR Champions and LPGA Tour have now used Newton shafts in competition. This marks a significant leap from earlier in the season, reflecting growing trust from elite players who value precision, consistency and innovation… One of Newton's most impactful endorsements came when Ken Duke became the first professional to officially sign with the brand, integrating the Newton Motion shaft into his bag for the 2024 season. His standout performance, ranking no. 1 in driving accuracy at the Constellation FURYK & FRIENDS, highlighted the shaft's consistency and power. ‘It's unbelievable how I can shape it,' Duke said. ‘Not only that, but I've gained 6–15 yards with it.'"

To view the full article, visit https://ibn.fm/FnwXo

Newton Golf Company Inc. (NASDAQ: NWTG), a Sacks Parente Company, is a technology-forward golf equipment manufacturer committed to enhancing player performance through innovative design. Since its founding in 2018, the company has developed a growing portfolio of premium golf products, including putters, golf shafts, grips, and related accessories. Its proprietary advancements include the First Vernier Acuity putter, patented Ultra-Low Balance Point (ULBP) technology, weight-forward Center-of-Gravity (CG) design, and ultra-light carbon fiber putter shafts.

As part of its commitment to growth in golf shaft technologies, the company expanded its manufacturing operations in April 2022, opening a dedicated facility in St. Joseph, Missouri. This move reinforced its goal of maintaining high-quality production standards while manufacturing and assembling substantially all of its products in the United States. In addition to golf clubs and accessories, Newton Golf Company is exploring expansion into golf apparel and other product categories.

The company sells its products through multiple channels, including resellers, its direct-to-consumer website, Club Champion retail stores, and distributors in the U.S., Japan, and South Korea. Future expansion may include growth through mergers, acquisitions, or the development of complementary product lines.

Newton Golf Company is headquartered in Camarillo, California.

Products

Newton Golf Company is focused on delivering high-performance golf equipment with a strong emphasis on precision engineering and cutting-edge materials. The company’s key product lines include:

• Newton Motion Golf Shafts: Launched in November 2023, these shafts are engineered with proprietary flex profiles designed for greater distance, reduced dispersion, and optimized performance across swing speeds. The company’s DOT system eliminates traditional shaft flex definitions, making it accessible to all golfers.
• Gravity Putters: Introduced in October 2024, these putters incorporate patented Ultra-Low Balance Point (ULBP) technology to improve stroke consistency and tighten putt dispersion. Manufactured in the U.S., they feature premium materials such as steel, aluminum, titanium alloys, and patented magnesium face plate technology.
• Golf Grips & Accessories: The company continues to innovate in this category, providing golfers with performance-enhancing grips and accessories to complement their clubs.

All Newton Golf Company products are manufactured with strict quality control standards to ensure precision and reliability, reinforcing the brand’s reputation for premium performance.

Market Opportunity

The global golf equipment market was valued at approximately $8 billion in 2022, with the U.S. market accounting for $2.9 billion. The golf club segment dominated the industry, representing 45.7% of total market share. Increasing participation in golf, particularly among younger players and women, is driving demand for high-quality, customizable golf equipment.

Key industry trends supporting growth include:

• The increasing popularity of premium, high-performance golf equipment among both professionals and amateurs.
• A shift toward customization, as golfers seek tailored products that enhance performance.
• A growing interest in golf from younger demographics, with amateur and collegiate golfers being particularly receptive to innovation.

Newton Golf Company’s emphasis on U.S.-based manufacturing provides it with a competitive edge in terms of supply chain efficiency, quality control, and sustainability, further strengthening its position in the market.

Leadership Team

Dr. Greg Campbell, Executive Chairman and Chief Executive Officer, brings nearly 40 years of experience in emerging technologies, product development, and public company leadership. He currently serves as CEO of V-Grid Energy Systems, a California-based company focused on converting agricultural waste into renewable electricity and bio-carbon. He has successfully taken two companies public and previously managed a $1.2 billion P&L as SVP & GM at Lam Research. Campbell holds a Ph.D. in Electrical and Electronics Engineering from UCLA and a BA/MA in Engineering from Cambridge University.

Ryan Stearns, Chief Financial Officer, was appointed in 2024 and oversees financial planning and corporate strategy. He brings expertise in scaling businesses and optimizing financial performance to support the company’s growth.

Newton Golf Company Inc. (NASDAQ: NWTG), closed Tuesday's trading session at $1.79, off by 1.6484%, on 108,988 volume. The average volume for the last 3 months is 156,671 and the stock's 52-week low/high is $1.35/$119.1.

Recent News

• Newton Golf Company Inc. (NASDAQ: NWTG) - InvestorNewsBreaks - Trusted by the Game's Elite: Newton Golf Company Inc. (NASDAQ: NWTG) Reaches New Milestone
• InvestorNewsBreaks - Newton Golf Company Inc. (NASDAQ: NWTG) Is Pushing the Boundaries of Performance in Growing Market 
• Newton Golf Company Inc. (NASDAQ: NWTG) Drives Momentum amid Record Growth in Golf Trials

Bollinger Innovations, Inc. (NASDAQ: BINI)

The QualityStocks Daily Newsletter would like to spotlight Bollinger Innovations, Inc. (NASDAQ: BINI).

A study conducted by researchers from Uppsala University's Ångström Advanced Battery Center has found that artificial intelligence can be used to improve the safety and lifespan of electric vehicle batteries. Led by materials chemistry Prof. Daniel Brandell, the research team built an artificial intelligence model that can accurately map how an EV battery will degrade as it ages over time, potentially opening the door to safer and longer-lasting electric vehicle batteries. With the global transition from internal combustion engine (ICE) cars to EVs losing momentum due to the rapid degradation of EV batteries, the AI tool could not have come at a better time. Rather than relying on extensive vehicle data collection, the system works with short charging segments, addressing both industry privacy concerns and user anonymization issues. The research team believes this approach will enable manufacturers to optimize battery performance while extending operational lifespans, ultimately making electric vehicles more reliable and cost-effective for consumers. By predicting potential safety issues before they occur, the technology could also prevent the design flaws and side reactions that currently plague battery systems. This AI tool could be a valuable complement or addition to the systems that EV makers like Bollinger Innovations, Inc. (NASDAQ: BINI) leverage in a bid to bring to market vehicles with batteries that perform reliably for a long time. 

Bollinger Innovations, Inc. (NASDAQ: BINI) is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with United States-based manufacturing located in Tunica, Mississippi.

In August 2023, Mullen began commercial vehicle production in Tunica. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The Company’s commercial dealer network consists of Papé Kenworth, Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key West Coast, Midwest, Pacific Northwest, New England, and Mid-Atlantic markets.

In September 2022, Bollinger Motors, of Oak Park, Michigan, became a majority-owned EV truck company of Mullen Automotive. Bollinger Motors has passed numerous milestones including its B4, Class 4 electric truck production launch on Sept. 16, 2024, and the development of a world-class dealer network with over 50 locations across the United States for sales and service support.

Mullen Commercial

Mullen is defining a new era in commercial vehicles with its connected and customized solutions aimed at making businesses more efficient and profitable.

Mullen ONE Class 1 EV Cargo Van

The Mullen ONE class 1 commercial electric vehicle is the first of its kind in the U.S. market. This van was designed to navigate within narrow urban streets and residential roads, all while maximizing payload and cargo space. The Mullen ONE’s height is less than 6.5 feet, meaning your driver can park the vehicle in a residential garage.

Mullen THREE Class 3 Electric Truck

The efficient urban utility low cab forward features a tight turning diameter of 38 feet and excellent visibility for superior maneuverability on narrow city streets. Even in reverse, maneuverability is a breeze with our standard backup camera and 7-inch display screen. This versatile chassis provides a clean top-of-rail for easy upfitting with bodies up to 14 feet long and over 5,300 lbs of payload. In addition, the design of the LCF chassis allows more cargo length within a given overall length.

Mullen Commercial EVs are eligible for several federal and state level EV incentives, which can be combined for maximized savings.

Mullen ONE:

• $7,500 Federal Tax Credit
• $3,500 MOR-EV Incentive (Massachusetts only)
• $7,500 ComEd Business & Public Sector EV Rebate Program (Illinois only)

Mullen THREE:

• $7,500 Federal Tax Credit
• $45,000 California’s Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project (HVIP) (California only)
• $15,000 MOR-EV Incentive (Massachusetts only)
• $30,000 ComEd Business & Public Sector EV Rebate Program (Illinois only)

In the last two years, Mullen has conducted over 100 vehicle demos or pilots across various industries in the U.S. resulting in significant progress, including new sales opportunities and vehicle orders received and or completed:

• Universities: Princeton University, University of Virginia (UVA), University of California, Los Angeles (UCLA)
• Local city governments: Cities of Dublin, Ohio, Raleigh, North Carolina, Los Angeles, California, Seattle, Washington and Orange County, North Carolina
• Small businesses: From local florist shops to health care providers delivering supplies

Mullen has an extensive dealer network in the U.S. with renowned dealers nationwide including:

• Papé Group (California, Oregon, Washington)
• National Auto Fleet Group (California)
• Pritchard EV (Iowa)
• Eco Auto (Massachusetts)
• Ziegler Truck Group (Minnesota)
• Range Truck Group (Washington)
• Mullen Commercial Vehicle Center (California)

Mullen Commercial EVs are available for purchase on Sourcewell under NAFG’s Sourcewell Contract # 091521-NAF which offers Class 1-3 light duty trucks, cars, vans, SUVs, cab chassis, and electric vehicles with related equipment and accessories to U.S. government agencies.

Bollinger Motors

Mullen entered the medium-duty truck classes through its September 2022 acquisition of a controlling interest in EV truck innovator Bollinger Motors. The acquisition gave Mullen access to a significant pipeline of interest from large companies for commercial electric truck classes 3-6 in a wide range of markets, such as last-mile delivery, refrigeration, utilities and upfitters.

The 2025 Bollinger B4 chassis cab is an all-new, all-electric Class 4 commercial truck designed from the ground up with extensive fleet and upfitter input. Bollinger’s unique chassis design protects the 158-kWh battery pack and components to offer unparalleled capability and safety in the commercial market. The vehicle also features a payload in excess of 7,300 pounds with an average driving range of 185 miles. Bollinger Motors began serial production of the B4 on Sept. 16 via its manufacturing partnership with Roush Industries at their facility in Livonia, Michigan.

Bollinger Motors has passed numerous milestones in recent months, including:

• 30 B4s delivered and paid for, worth nearly $4.5 million, since start of production
• Its production launch on Sept. 16 at Roush Industries in Livonia, Michigan
• Achieving FMVSS compliance
• Receiving the Certificate of Conformity from the Environmental Protection Agency, and CARB certification
• The creation of a world-class dealer and service network
• An agreement with Our Next Energy in Novi, Michigan, for battery packs
• Providing a full warranty coverage of the B4 chassis cab
• Announcing Syncron as its warranty administration partner and Amerit Fleet Solutions as its mobile service provider
• A partnership with EO to power EV charging infrastructure, equipment and technology solutions for Bollinger’s dealers and customers

Bollinger Motors has qualified for multiple federal and state incentive programs, including:

• Inflation Reduction Act incentives of up to $40,000 per vehicle
• California: Innovative Small e-Fleet (ISEF) Pilot Program, with incentives up to $120,000 per vehicle
• Massachusetts: voucher of up to $30,000 per vehicle from Massachusetts Offers Rebates for Electric Vehicles (MOR-EV)
• New York: up to $100,000 from NYTVIP through NYSERDA
• Pennsylvania: up to a $20,000 grant from Alternative Fuels Incentive Grant Program (AFIG) of the Pennsylvania Department of Environmental Protection

Mullen FIVE RS

The Mullen FIVE RS is an ultra-high-performance EV Crossover featuring a top speed of over 200 mph and acceleration from 0-60 mph in under 2 seconds. The FIVE RS is equipped with 800-volt architecture, all-wheel drive, two-speed gearbox, and over 1,100 horsepower.

The Mullen FIVE RS is planned for launch in Germany with vehicle sales planned for December 2025. Initial vehicle market territories include the EU in 2025, followed by the UAE and South Africa in early 2026.

Mullen is partnering with Faissner Petermeier Fahrzeugtechnik AG (“FPF”), which has decades of experience in the development and production of serial components and sophisticated vehicles for global brands such as Piech Automotive, Gumpert Automotive and is in partnership with BMW of all the above. FPF is certified according to the IATF standard and fulfills all the special requirements of the Federal Motor Transport Authority in Germany.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

Mullen is led by an executive team with extensive EV, OEM and high-growth startup experience.

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working towards a sustainable future by creating a suite of clean-energy, electric vehicles at varied price points. With entirely US based manufacturing and operations, Mr. Michery is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Bollinger Innovations, Inc. (NASDAQ: BINI), closed Tuesday's trading session at $0.303, off by 19.7351%, on 14,495,674 volume. The average volume for the last 3 months is 12,585,700 and the stock's 52-week low/high is $0.2936/$6150000000.

Recent News

• Bollinger Innovations, Inc. (NASDAQ: BINI) - AI Can Improve EV Battery Lifespan and Safety, Study Finds
• Falling Battery Prices Could Accelerate EV Uptake 
• US Household Power Bills Surge 10% as Tariffs, Policy Changes Bite

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF)

The QualityStocks Daily Newsletter would like to spotlight Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF).

The company's rebranding reflects Izotropic's refined corporate positioning and emphasizes its focus on key people across the healthcare ecosystem

Izotropic's strategic positioning becomes even more critical when considering the magnitude of the opportunity ahead

Izotropic has the exclusive global licensing rights to breast CT technology, and IzoView is the commercial model

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) , a medical device company focused on imaging-based products for breast cancer care, announced plans for a non-brokered private placement of up to 1.2 million units at $0.25 each to raise gross proceeds of up to $300,000. Each unit will include one common share and one transferable warrant exercisable at $0.50 for three years. Proceeds will be used for general working capital. The Company also extended the expiry of 2,841,325 warrants issued in September 2023 by one year to September 20, 2026, with all other terms unchanged. The warrant extension remains subject to final CSE approval.

To view the full press release, visit https://ibn.fm/5hDeL

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) is a medical device company advancing dedicated imaging solutions to improve the screening, diagnosis, and treatment of breast cancer. Focused exclusively on this clinical area, Izotropic is developing purpose-built technologies designed to address persistent limitations in conventional breast imaging. Through innovation in both device architecture and image acquisition, the company aims to enhance diagnostic confidence while improving patient experience.

Izotropic’s mission is to deliver transformative tools that empower radiologists, reduce missed cancers, and streamline clinical workflows. By introducing a next-generation imaging platform for breast cancer screening and diagnosis, the company is targeting a clear unmet need in a multibillion-dollar global market. Its vision centers on redefining how breast imaging is performed—shifting away from adaptations of whole-body scanners or 2D mammography toward a fully dedicated approach optimized for breast anatomy.

The company’s strategy is built around a singular platform with expansion potential. Izotropic is focused on commercializing its lead product through a staged pathway that includes regulatory authorization, clinical validation, and strategic investor engagement. In parallel, the company is developing educational tools and communications platforms to raise awareness among patients, clinicians, and stakeholders about the evolving role of dedicated breast imaging technologies in cancer care.

The company is headquartered in Vancouver, British Columbia, with operations in Sacramento, California.

Technology Portfolio

Izotropic’s flagship product is the IzoView Breast CT Imaging System, a dedicated breast imaging platform offering high-resolution, true 3D visualization without compression. The IzoView system was advanced from academic innovation to commercial readiness by Izotropic’s in-house team, building on exclusively licensed technology developed at the University of California, Davis to optimize diagnostic accuracy, patient comfort, and clinical workflow. IzoView integrates proprietary mechanical design, patented hardware innovations, and trade-secret software algorithms, along with AI-driven enhancements designed to improve radiologist performance.

Now in clinical-ready form and housed at Izotropic’s engineering facility in Sacramento, California, IzoView was built under an ISO 13485-compliant quality management system. It is scheduled for use in the company’s planned U.S. clinical trial for FDA market authorization. The device is also central to the company’s broader commercialization strategy, which includes platform extensions and future imaging-based product lines outlined in its recently completed 150-page business plan and financial model.

In preparation for launch, Izotropic is also rolling out strategic awareness platforms. These include a company-hosted podcast and the development of breastct.com, a new educational resource to support patients, clinicians, and stakeholders. These initiatives are designed to enhance engagement, reinforce brand positioning, and build early market traction for IzoView.

Market Opportunity

Izotropic is targeting the global breast imaging market, which is undergoing rapid innovation as healthcare providers seek more accurate, patient-friendly alternatives to traditional mammography. Current screening technologies have well-documented limitations in detecting tumors in women with dense breast tissue, a challenge IzoView directly addresses.

According to a report by MarketsandMarkets, the breast imaging market is projected to grow from $4.3 billion in 2023 to $6.6 billion by 2028, at a compound annual growth rate (CAGR) of 8.9%. Key drivers include the increasing prevalence of breast cancer, the shift toward early detection, and advances in imaging technology such as AI integration and contrast-enhanced diagnostics.

Izotropic’s licensing structure with UC Davis allows the company to pursue either FDA or CE Mark approval, offering flexibility for U.S. and international market entry. Izotropic’s go-to-market plan is supported by ongoing education efforts and a structured clinical strategy, both aligned to accelerate adoption and unlock value in a growing global market.

Leadership Team

Robert Thast, Interim CEO, is the founding executive of Izotropic and has over 30 years of experience leading public companies. He has raised over $100 million in capital, built cross-functional leadership teams, and guided early-stage ventures through public listings and strategic transitions. At Izotropic, he oversees corporate development, financing, and market strategy.

Dr. John Boone, Ph.D., Principal Founder and Director, is a Distinguished Professor of Radiology and Biomedical Engineering at UC Davis. He is a pioneer in breast CT development, having built and tested four dedicated scanners and led trials with nearly 500 women. He has held top roles in AAPM and RSNA and currently serves as Editor-in-Chief of Medical Physics.

Ralph Proceviat, CPA, CFO and Director, brings more than four decades of experience in finance, restructuring, and cross-border operations. He has served as CEO, President, and CFO across multiple sectors and has raised significant capital for both public and private ventures. He is also the founder of C-Suite-Consulting.

Dr. Younes Achkire, Ph.D., Chief Operating Officer and Lead Engineer, is the technical lead behind IzoView. He previously co-founded Zap Surgical Systems and has commercialized FDA-cleared technologies in medtech and clean energy. At Izotropic, he manages engineering, manufacturing, clinical deployment, and operational scale-up.

Izotropic Corp. (OTCQB: IZOZF), closed Tuesday's trading session at $0.2171, off by 3.7677%, on 75,454 volume. The average volume for the last 3 months is 44,130 and the stock's 52-week low/high is $0.0186/$0.33.

Recent News

• Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) - Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Unveils Comprehensive Brand Identity Transformation to Position Company for Commercial Launch
• TechMediaBreaks - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Announces $300K Private Placement and Warrant Extension
• Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): How a $500K Device Could Reshape the $8.7 Billion Breast Imaging Market

Nightfood Holdings Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings Inc. (OTCQB: NGTF).

Nightfood Holdings (OTCQB: NGTF) , through its wholly owned subsidiary Future Hospitality Ventures Holdings Inc. ("FHVH"), operating as RoboOp365, recently signed a binding letter of intent with Stratford Education Group Inc., doing business as Los Angeles Cooking School ("LACS"), to form Modern Culinary Systems Inc. "This partnership represents the first culinary school in the U.S. to integrate artificial intelligence automation into its core curriculum," reads an article discussing the strategic move. "The culinary education market represents substantial opportunity, with the U.S. segment valued at approximately $32.5 billion in 2023 according to IBISWorld. Modern Culinary Systems enters this market with a differentiated value proposition: preparing students for the actual working environment they'll encounter in their careers."

"By being the first to bring AI automation into the culinary school setting, we are giving students hands-on access to the same transformative technologies reshaping kitchens across the globe," stated Sonny Wang, CRO of Nightfood Holdings and CEO of FHVH.

To view the full article, visit https://ibn.fm/Np0ob

Nightfood Holdings Inc. (OTCQB: NGTF) is a hospitality technology and asset acquisition company revolutionizing hotel operations through AI-driven service robotics and strategic property acquisitions. By integrating advanced automation solutions with high-value hospitality assets, NGTF is setting a new standard for operational efficiency, cost reduction, and labor optimization in the hospitality industry.

With a focus on Robotics-as-a-Service (RaaS) and hotel ownership, NGTF is uniquely positioned at the intersection of technology and real estate, creating scalable, revenue-generating solutions that drive the widespread adoption of automation in the hospitality sector.

Operations

Nightfood Holdings is focused on two core business areas:

• Hotel Acquisitions & Operations – NGTF is acquiring a portfolio of independent hospitality properties, spanning various market segments from midscale to luxury. These hotels serve as real-world testbeds for automation technologies, allowing NGTF to refine its RaaS solutions before deploying them at scale.
• Robotics-as-a-Service (RaaS) for Hospitality – NGTF provides subscription-based, AI-driven robotic automation, designed to optimize hotel operations. By deploying standardized automation solutions, NGTF helps hotels reduce costs, improve labor efficiency, and enhance guest experiences.

Through this fully integrated model, NGTF ensures that its robotics solutions are tested, optimized, and proven profitable before expanding to third-party hotel operators.

Market Opportunity

The demand for automation in hospitality is accelerating, driven by labor shortages, rising costs, and increased competition. NGTF is positioned to capitalize on this shift through its combined hotel ownership and RaaS strategy.

• Total Addressable Market (TAM): The global service robotics market is projected to reach approximately $107.75 billion by 2030, driven by widespread adoption across industries including hospitality, according to Research and Markets.
• Serviceable Available Market (SAM): The global smart hospitality market, which includes AI and automation technologies for hotels, is projected to reach $186.10 billion by 2032, according to SNS Insider.
• Competitive Positioning: NGTF’s unique real estate + automation model allows it to implement cost-saving robotics solutions in real-world environments before expanding adoption across the industry.

Industry Impact: The Future of Smart Hotels

NGTF is at the forefront of next-generation hospitality automation, transforming how hotels operate. By combining AI-powered service robotics with real estate acquisitions, NGTF is pioneering the transition to smart, highly efficient hotel environments.

Hotels acquired by NGTF serve as testing grounds for robotics deployment, allowing the company to continuously refine its automation solutions. The biggest industry benefits include:

• Cost Savings for Hotel Operators – Reducing labor costs and improving operational efficiency.
• Scalability & Standardization – Offering a streamlined, subscription-based RaaS model for seamless automation adoption.
• Industry Leadership in Hotel Robotics – Driving the transformation of hospitality with AI-powered automation solutions.

Future Vision & Growth Strategy

Over the next three to five years, NGTF is committed to scaling both its hotel portfolio and RaaS adoption. By refining and optimizing its automation technologies in its own properties, NGTF will continue deploying RaaS to third-party hotel operators, positioning itself as a leader in next-generation hospitality automation.

Through strategic acquisitions and AI-driven solutions, NGTF is defining the future of smart hotels—delivering cost-efficient, scalable automation that reshapes the hospitality landscape.

Team Expertise as a Strategic Advantage

In addition to technology and real estate, NGTF’s most powerful asset is its team. The company’s leadership and operating partners bring deep expertise in both hospitality and food service, having collectively developed over 50 properties, managed more than 130 hotels, and supported more than 6,000 quick-service restaurants.

This wealth of experience enables NGTF to execute its automation and acquisition strategy with operational discipline, industry insight, and scale—further strengthening its position in next-generation hospitality.

Nightfood Holdings Inc. (OTCQB: NGTF), closed Tuesday's trading session at $0.0281, off by 2.4306%, on 460,154 volume. The average volume for the last 3 months is 632,670 and the stock's 52-week low/high is $0.0053/$0.0571.

Recent News

• Nightfood Holdings Inc. (OTCQB: NGTF) - AINewsBreaks - Nightfood Holdings Inc. (NGTF) Set to Revolutionize Culinary Education with AI
• Nightfood Holdings Inc. (NGTF) Bets $80 Million on AI-Powered Hotel Revolution
• AINewsBreaks - Nightfood Holdings Inc. (OTCQB: NGTF) Showcased in NNW Editorial on AI-Driven Hospitality Revolution